BOSTON, June 7, 2016 /PRNewswire/ -- Intarcia Therapeutics, Inc. introduced today the Medici Drug Delivery SystemTM, its innovative proprietary subcutaneous delivery system, comprised of three unique technologies: a matchstick-sized osmotic mini-pump that is placed just beneath the skin to deliver a continuous and consistent flow of medication; a placement technology designed for a simple, relatively quick and highly reliable user experience; and a stabilization technology for proteins, peptides, antibody fragments, and other high-potency small molecules. The System will be on display later this month at the American Diabetes Association's 76th Scientific Sessions in New Orleans.
"Delivering drugs via our new technology has the potential to open up a new way of delivering novel medicines just once-yearly," said Kurt Graves, Chairman, President and CEO of Intarcia. "One of the biggest problems in chronic diseases is millions of patients lack effective control of their condition due to sub-optimal effectiveness of their medication, and the fact is, the majority of patients with chronic conditions stop taking these pills and injections, after just three-to-six months. We are aiming to address these serious and costly unmet needs by introducing a new way to deliver once-yearly therapies that hold the potential for game-changing improvements in outcomes and patient adherence over time. We believe that our novel technology platform, the Medici Drug Delivery System, represents the potential for a renaissance in medicine delivery for the treatment of major chronic diseases."
The osmotic mini-pump can be quickly and simply placed by a trained physician, physician assistant, or nurse practitioner. Once placed just beneath the skin, water from the extracellular fluid enters the pump device at one end – by diffusing through a semi-permeable membrane directly into a salt osmotic engine – that expands to drive a piston at a controlled rate. This forces the drug within the pump to be released in a steady, consistent fashion at the distal end of the device.
Each osmotic mini-pump is designed to hold an appropriate volume of drug product to treat a patient for a predetermined extended duration of time. One of the unique aspects of the System is the stabilization technology – proteins, peptides, antibody fragments, and other high-potency small molecules may be stabilized at or above human body temperatures for extended periods of time.
The Medici Drug Delivery System™ has the potential to be used in chronic conditions such as diabetes, obesity, autoimmune, and other serious diseases. Intarcia is currently researching new therapies, including combination products, to use within its drug delivery technology (proteins, peptides, antibody fragments, and other high-potency small molecules).
About Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapies to enhance treatment outcomes by optimizing and improving the efficacy, continuous administration and tolerability of drug therapies. Delivering medicines for up to a year and beyond has the potential to ensure improved patient adherence and compliance, which is very poor in most chronic diseases. Intarcia's drug development expertise and competitive edge are demonstrated by its abilities to stabilize proteins, peptides, antibody fragments, and other high-potency small molecules at or above body temperature, and to deliver them in a constant and consistent manner via Intarcia's proprietary technology platform, the Medici Drug Delivery SystemTM. Intarcia continues to conduct research and development, utilizing its platform technology, to treat other chronic, serious disorders such as diabetes, obesity, autoimmune, and other serious diseases. For more information on the Company, please visit www.intarcia.com.
Intarcia and its logo are registered trademarks of Intarcia Therapeutics, Inc.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/intarcia-announces-branding-of-the-medici-drug-delivery-system----a-platform-of-technologies-key-to-advancing-its-pipeline-of-once-yearly-peptide-and-antibody-fragment-based-therapeutics-in-poorly-controlled-chronic-diseases-300279739.html
SOURCE Intarcia Therapeutics, Inc.